Galectin Therapeutics, based in Norcross, Georgia, focuses on developing therapies for fibrotic diseases, severe skin diseases, and cancer, with its lead drug, belapectin, targeting galectin-3. The company, with 14 employees, has programs for metabolic dysfunction-associated steatohepatitis and advanced cancers.
Kevin D Freeman bought 10,000 shares of GALT on 16 October at $2.70 per share, worth a total of $27K. They now own 80,000 GALT shares, or a 14% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
